- ホーム
- > 洋書
- > 英文書
- > Science / Mathematics
Full Description
Drug Discovery and Development, Third Edition presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing. This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Features:
Highlights emerging scientific fields relevant to drug discovery such as the microbiome, nanotechnology, and cancer immunotherapy; and novel research tools such as CRISPR and DNA-encoded libraries
Case study detailing the discovery of the anti-cancer drug, lorlatinib
Venture capitalist commentary on trends and best practices in drug discovery and development
Comprehensive review of regulations and their impact on drug development, highlighting special populations, orphan drugs, and pharmaceutical compounding
Multidiscipline functioning of an Academic Research Enterprise, plus a chapter on Ethical Concerns in Research
Contributions by 70+ experts from industry and academia specialists who developed and are practitioners of the science and business
Contents
Acknowledgments Introduction to the First Edition (1992) Introduction to the Second Edition (2006) Editors Contributors Chapter 1 Introduction to Drug Discovery and Development James J. O'Donnell III, John C. Somberg, and James T. O'Donnell SECTION I Overview Chapter 2 Current Opinions on the Trajectory of the Pharmaceutical Development John C. Somberg Chapter 3 Innovation in Drug Development: Perspectives of a Venture Capitalist Krishna Yeshwant SECTION II Drug Discovery Chapter 4 High-Throughput Screening Omar Perez, J. Pena, Virneliz Fernandez-Vega, Louis Scampavia, and Timothy Spicer Chapter 5 DNA-Encoded Compound Libraries: An Emerging Paradigm in Drug Hit Discovery Raphael M. Franzini Chapter 6 Bio-Targeted Nanomaterials for Theranostic Applications Sabyasachi Maiti and Kalyan Kumar Sen Chapter 7 The Development of Adoptive T-Cell Immunotherapies for Cancer: Challenges and Prospects David J. Dow, Steven J. Howe, Mala K. Talekar, and Laura A. Johnson Chapter 8 CRISPR in Drug Discovery Chih-Shia Lee and Ji Luo Chapter 9 Probiotics in the World: "Bugs-as-Drugs" Thomas Kuntz, Madeline Kim, Elle Simone Hill, Mariana C. Salas Garcia, and Jack A. Gilbert Chapter 10 Discovery and Early Development of the Next-Generation ALK Inhibitor, Lorlatinib (18): Agent for Non?Small-Cell Lung Cancer Paul F. Richardson SECTION III Drug Development Chapter 11 Integrated Drug Product Development: From Lead Candidate Selection to Life-Cycle Management Madhu Pudipeddi, Abu T.M. Serajuddin, Ankita V. S
